Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy
Abstract
Background There is no information about the frequency of liver dysfunction in patients with inflammatory bowel disease (IBD) treated with immunosuppressants and infected with hepatitis B (HBV) and/or C virus (HCV). Aim To assess the influence of immunosuppressants on the course of HBV and HCV infection in IBD. Methods Patients with IBD with HBV and/or HCV infection from 19 Spanish hospitals were included. Clinical records were reviewed for the type of immunosuppressant used, treatment duration, liver function tests and viral markers before, during and after each immunosuppressant. Logistic and Cox regression analysis were used to identify predictors of outcome. Results 162 patients were included; 104 had HBV markers (25 HBsAg positive) and 74 had HCV markers (51 HCV-RNA positive), and 16 patients had markers of both infections. Liver dysfunction was observed in 9 of 25 HBsAg positive patients (36%), 6 of whom developed hepatic failure. Liver dysfunction in HCV was observed in 8 of 51 HCV-RNA positive patients (15.7%), and only one developed hepatic failure. The frequency and severity of liver dysfunction was significantly higher in HBV-infected patients than in HCV-infected patients (p=0.045 and p=0.049, respectively). Treatment with ≥2 immunosuppressants was an independent predictor of HBV reactivation (OR 8.75; 95% CI 1.16 to 65.66). The majority of patients without reactivation received only one immunosuppressant for a short period and/or prophylactic antiviral treatment. No definite HBV reactivations were found in anti-HBc positive patients lacking HBsAg. Conclusion Liver dysfunction in patients with IBD treated with immunosuppressants is more frequent and severe in those with HBV than in HCV carriers and is associated with combined immunosuppression.Keywords
This publication has 34 references indexed in Scilit:
- European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel diseaseJournal of Crohn's and Colitis, 2009
- The natural history of chronic hepatitis B virus infection #Hepatology, 2009
- Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in preventionEuropean Journal of Clinical Microbiology & Infectious Diseases, 2008
- Management of viral hepatitis in hematologic malignanciesBlood Reviews, 2008
- Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohnʼs disease patientInflammatory Bowel Diseases, 2007
- Occult Hepatitis B and Infliximab-induced HBV ReactivationInflammatory Bowel Diseases, 2007
- Chronic hepatitis BHepatology, 2007
- Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infectionJournal of Hepatology, 2006
- Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled studyJournal of Hepatology, 2005
- Infliximab Therapy for Crohn?s Disease in a Patient with Chronic Hepatitis BDigestive Diseases and Sciences, 2005